Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STRIDE: EN3835 vs Placebo in Plantar Fibromatosis
NCT06151197Phase 3Completed
- Sponsor
- Keenova Therapeutics
- Start
- Nov 2023
- Primary completion
- Jun 2026
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in plantar fibromatosis comparing EN3835 with Placebo (2 arms). Primary endpoint: Average Daily Pain Score at 12 weeks. Started Nov 2023; status: completed.
02
Drugs
collagenase clostridium histolyticum
03
Conditions
plantar fibromatosis
Beyond the preview
Go deeper on NCT06151197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06151197.